Phase I/II Trial of Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma
Latest Information Update: 23 Nov 2024
At a glance
- Drugs Dexamethasone (Primary) ; Ixazomib (Primary) ; Mezigdomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 19 Nov 2024 Status changed from recruiting to withdrawn prior to enrolment, due to closure of the trial as per BMS.
- 03 Nov 2023 Status changed from not yet recruiting to recruiting.
- 25 Sep 2023 New trial record